NewLimit

NewLimit is a San Francisco-based biotechnology company that is developing anti-aging solutions. The company was founded in late 2021 and was initially launched with more than $105 million in funding from its own founders. The focus of NewLimit is developing epigenetic reprogramming medicines, which can possibly treat age-related diseases. The company states that its focus is on improving the "healthspan" of people and not the lifespan, meaning the focus is on the quality of life, not the number of years that someone lives.

NewLimit is building a platform that acts as a discovery engine to aid with its research and development. The platform is being designed to discover and develop epigenetic reprogramming therapies on a large scale. It uses a combination of technologies, such as machine learning and functional genomics, to test different reprogramming interventions for every experiment. This allows the program to gain insights into how the reprogramming impacts function and to select the most promising interventions to develop.

The platform is intended to be used to create anti-aging products that could help with diseases that are generally associated with aging, such as dementia. As of April 2023, the company has started running reprogramming screens as part of its research efforts.

Results from NewLimit's research that were shared in a blog in April 2023